Te-Hui Kuo

Te-Hui Kuo

Auto-generated profile, based on publicly available information

Te-Hui Kuo

Division of Nephrology, Department of Internal Medicine, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Tainan, Taiwan

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 2015 in Journal of Microbiology, Immunology and Infection
Verified
Journal Article
Closed access
MWMing-Cheng Wang
Ming-Cheng Wang
WLWei-Hung Lin
Wei-Hung Lin
JYJing-Jou Yan
Jing-Jou Yan
HFHsin-Yi Fang
Hsin-Yi Fang
TKTe-Hui Kuo
Te-Hui Kuo
JWJiunn-Jong Wu
Jiunn-Jong Wu

17 July 2019 in BMC Nephrology
Verified
Journal Article
Open access
PDF file
TKTe-Hui Kuo
Te-Hui Kuo
WLWei-Hung Lin
Wei-Hung Lin
JCJo-Yen Chao
Jo-Yen Chao
AWAn-Bang Wu
An-Bang Wu
CTChin-Chung Tseng
Chin-Chung Tseng
MWMing-Cheng Wang
Ming-Cheng Wang
Sclerostin, an antagonist of the Wingless-type mouse mammary tumor virus integration site (Wnt) pathway that regulates bone metabolism, is a potential contributor of chronic kidney disease (CKD)–mineral and bone disorder (MBD), which has various forms of presentation, from osteoporosis to vascular calcification. The positive association of sclerostin with bone mineral density (BMD) has been demonstrated in CKD and hemodialysis (HD) patients but not in peritoneal dialysis (PD) patients. This study assessed the association between sclerostin and BMD in PD patients. Eighty-nine PD patients were enrolled; their sera were collected for measurement of sclerostin and other CKD–MBD-related markers. BMD was also assessed simultaneously. We examined the relationship between sclerostin and each parameter through Spearman correlation analysis and by comparing group data between patients with above- and below-median sclerostin levels. Univariate and multiple logistic regression models were employed to define the most predictive of sclerostin levels in the above-median category. Bivariate analysis revealed that sclerostin was correlated with spine BMD (r = 0.271, P = 0.011), spine BMD T-score (r = 0.274, P = 0.010), spine BMD Z-score (r = 0.237, P = 0.027), and intact parathyroid hormone (PTH; r = − 0.357, P < 0.001) after adjustments for age and sex. High BMD, old age, male sex, increased weight and height, diabetes, and high osteocalcin and uric acid levels were observed in patients with high serum sclerostin levels and an inverse relation was noticed between PTH and sclerostin. Univariate logistic regression analysis demonstrated that BMD is positively correlated with above-median sclerostin levels (odds ratio [OR] = 65.61, P = 0.002); the correlation was retained even after multivariate adjustment (OR = 121.5, P = 0.007). For the first time, this study demonstrated a positive association between serum sclerostin levels and BMD in the PD population.

1 February 2022 in Journal of the Formosan Medical Association
Verified
Journal Article
Open access
CLChia-Chun Lee
Chia-Chun Lee
CHChih-Cheng Hsu
Chih-Cheng Hsu
MLMing-Huang Lin
Ming-Huang Lin
JSJunne-Ming Sung
Junne-Ming Sung
TKTe-Hui Kuo
Te-Hui Kuo
The prevalence of end-stage kidney disease (ESKD) in Taiwan has been increasing in recent decades. ESKD care and medical expenditures constitute an important part of the entire healthcare system. This study analyzed data collected from the National Health Insurance (NHI) Research Database from 2010 to 2018. The annual medical cost increased by approximately 4% both in the entire Taiwanese population and in its ESKD population. The total medical expenditure in the ESKD population from 2010 to 2018 increased from 48.03 to 65.65 billion reimbursement points, with dialysis treatments costing higher than non-dialysis treatments. ESKD outpatient and inpatient costs accounted for 10.4%-11.1% and 4.8%-5.6% of the entire NHI expenditure, respectively. The leading cause of inpatient costs was circulatory diseases, accounting for 29.3% of the total ESKD inpatient costs in 2018. Furthermore, percutaneous coronary intervention had the highest cost followed by simple percutaneous transluminal angioplasty. In 2018, the hemodialysis population had the highest average monthly cost of 73 thousand points per person, while the kidney transplant population had the lowest average monthly cost of 39 thousand points per person. Medical expenditure, including both inpatient and outpatient costs, of the ESKD population continued to grow from 2010 to 2018. The non-dialysis cost in the ESKD population was mainly for cardiovascular disease management and vascular access care, for which prevention will always be challenging.

4 November 2013 in International Journal of Rheumatic Diseases
Verified
Journal Article
Closed access
PDF file
WLWei-Hung Lin
Wei-Hung Lin
Chao-Yu GuoChao-Yu Guo
Chao-Yu Guo
WWWei-Ming Wang
Wei-Ming Wang
DYDeng-Chi Yang
Deng-Chi Yang
TKTe-Hui Kuo
Te-Hui Kuo
MWMing-Cheng Wang
Ming-Cheng Wang

20 February 2025 in Journal of Infection and Public Health
Verified
Journal Article
Open access
DYDeng-Chi Yang
Deng-Chi Yang
JCJo-Yen Chao
Jo-Yen Chao
CHChih-Yen Hsiao
Chih-Yen Hsiao
CTChien-Tzu Tseng
Chien-Tzu Tseng
WLWei-Hung Lin
Wei-Hung Lin
MWMing-Cheng Wang
Ming-Cheng Wang
Urinary tract infection (UTI) or acute pyelonephritis can lead to renal scarring and impact the subsequent renal function progression. The aims of this study were to investigate the changes in renal function related to UTI requiring hospital admission (UTI/HA) and the association between UTI/HA and long-term renal outcomes in patients with chronic kidney disease (CKD). This was a multicenter, retrospective observational study. Renal events and renal function before and after UTI/HA in CKD patients were analyzed for short-term and mid-term renal outcomes. A case-control study with multivariate logistic regression analysis was used to investigate the association between clinical characteristics and risk of long-term renal outcomes (kidney replacement therapy or death, KRT/death) in adult CKD patients. This study included 1062 adult CKD patients, with 340 KRT and 76 deaths identified during a median follow-up of 105 months. Among 174 patients with UTI/HA, 59 (33.9 %) had bacteremia, 90 (51.7 %) acute kidney injury (AKI), and one in-hospital mortality. There was a faster decline rate of estimated glomerular filtration rate (eGFR) after UTI/HA compared to the pre-UTI/HA period [median (IQR) 0.37 (0.17-0.72) versus 0.19 (0.06-0.36) ml/min/1.73 m2 per month, P < 0.0001]. The incidence of UTI/HA was similar between the KRT/death and the CKD non-dialysis groups. Multivariate logistic regression analysis showed that baseline eGFR, baseline eGFR decline rate and number of hospital admission were significantly associated with an increased risk of KRT/death. This study highlights the impact of UTI/HA on renal function and renal outcomes in adult CKD patients. It demonstrates a high incidence of in-hospital AKI but low mortality, and accelerated deterioration of renal function following UTI/HA. Long-term renal outcomes were influenced by the baseline renal function and progression rate, and the frequency of hospital admission. UTI/HA may be regarded as a potentially modifiable factor for CKD progression. However, there is a need for further analysis to isolate the impact of UTI/HA from pre-existing renal function decline on long-term renal outcomes.

28 February 2024 in Journal of the Formosan Medical Association
Verified
Journal Article
Open access
TKTe-Hui Kuo
Te-Hui Kuo
YCYa-Hui Chang
Ya-Hui Chang
LKLi-Jung Elizabeth Ku
Li-Jung Elizabeth Ku
WLWei-Hung Lin
Wei-Hung Lin
JCJo-Yen Chao
Jo-Yen Chao
Chung-Yi LiChung-Yi Li
Chung-Yi Li
The optimal timing of vascular access (VA) creation for hemodialysis (HD) and whether this timing affects mortality and health-care utilization after HD initiation remain unclear. Thus, we conducted a population-based study to explore their association. We used Taiwan's National Health Insurance Research Database to analyze health-care outcomes and utilization in a cohort initiating HD during 2003-2013. We stratified patients by the following VA creation time points: >180, 91-180, 31-90, and ≤30 days before and ≤30 days after HD initiation and examined all-cause mortality, ambulatory care utilization/costs, hospital admission/costs, and total expenditure within 2 years after HD. Cox regression, Poisson regression, and general linear regression were used to analyze mortality, health-care utilization, and costs respectively. We identified 77,205 patients who started HD during 2003-2013. Compared with the patients undergoing VA surgery >180 days before HD initiation, those undergoing VA surgery ≤30 days before HD initiation had the highest mortality-15.92 deaths per 100-person-years, crude hazard ratio (HR) 1.56, and adjusted HR 1.28, the highest hospital admissions rates- 2.72 admission per person-year, crude rate ratio (RR) 1.48 and adjusted RR 1.32, and thus the highest health-care costs- US$31,390 per person-year, 7% increase of costs and 6% increase with adjustment within the 2-year follow-up after HD initiation. Late VA creation for HD can increase all-cause mortality, hospitalization, and health-care costs within 2 years after HD initiation. Early preparation of VA has the potential to reduce post-HD mortality and healthcare expenses for the ESKD patients.